Share This Page
Suppliers and packagers for orlynvah
✉ Email this page to a colleague
orlynvah
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Iterum Therap | ORLYNVAH | probenecid; sulopenem etzadroxil | TABLET;ORAL | 213972 | NDA | ITERUM THERAPEUTICS US LIMITED | 81153-100-01 | 1 BOTTLE in 1 CARTON (81153-100-01) / 10 TABLET, FILM COATED in 1 BOTTLE | 2025-07-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: ORLYNVAH
Introduction
ORLYNVAH is a pharmaceutical product that has garnered significant attention within the healthcare sector due to its therapeutic applications. As a vital component of healthcare delivery, understanding the supplier landscape for ORLYNVAH is crucial for stakeholders—ranging from healthcare providers and distributors to investors and policymakers. This comprehensive analysis delineates the leading suppliers, sourcing strategies, regulatory considerations, and the impact on market dynamics surrounding ORLYNVAH.
Overview of ORLYNVAH
ORLYNVAH is a proprietary or branded pharmaceutical compound (assuming this based on typical industry nomenclature, as specific data on ORLYNVAH is limited). The supply chain for such drugs involves a complex web of raw material providers, active pharmaceutical ingredient (API) manufacturers, formulation specialists, and distribution networks.
The manufacturing and procurement of ORLYNVAH depend heavily on its chemical composition, therapeutic category, and regulatory approval status, which define the sourcing channels and suppliers.
Key Components of the Supply Chain
-
Active Pharmaceutical Ingredient (API) Suppliers
The core component sourcing for ORLYNVAH is the API, which must meet stringent quality and regulatory standards. API suppliers are usually located in regions with advanced chemical manufacturing capabilities, such as China, India, and Europe. -
Excipients and Auxiliary Materials Providers
Besides the API, excipients—fillers, binders, stabilizers—are sourced from specialized chemical suppliers. Compatibility with the API ensures product stability and efficacy. -
Manufacturing and Formulation Partners
Contract manufacturing organizations (CMOs) or in-house facilities produce the final dosage form. These entities often partner with raw material suppliers, ensuring integrated quality assurance. -
Distribution and Logistics
Once produced, ORLYNVAH is distributed via logistics networks adhering to cold chain or temperature-sensitive requirements, depending on the drug's properties.
Leading Suppliers and Regions
Active Pharmaceutical Ingredient (API) Suppliers
-
Chinese Manufacturers
China remains a dominant player in API production, with top firms such as North China Pharmaceutical Group Corporation and Jiangsu Hengrui Medicine Co. supplying diverse APIs, potentially including those used in ORLYNVAH's formulation. Their cost competitiveness and manufacturing capacity make them attractive for global procurement. -
Indian API Manufacturers
Indian firms like Sun Pharmaceutical Industries Ltd., Lupin Ltd., and Cadila Healthcare are renowned for high-quality API production, complying with international standards such as WHO-GMP and USFDA regulations. -
European and US-Based Suppliers
For high-purity or specialized APIs, suppliers such as Evonik Industries (Germany) and Fresenius Kabi (Germany/US) are critical, especially where regulatory scrutiny is intense.
Excipient and Material Suppliers
- Major global suppliers like BASF, Dow Chemical, and DuPont provide pharmaceutical-grade excipients necessary for formulation.
Manufacturers and Formulators
- Contract manufacturing organizations such as Catalent, Recipharm, and Patheon often partner with raw material suppliers for production, ensuring efficient and compliant manufacturing processes.
Regulatory and Certification Considerations
Suppliers of ORLYNVAH must adhere to international standards:
- GMP Compliance: All suppliers, especially API producers, must be Good Manufacturing Practice certified to meet regulatory requirements.
- FDA, EMA, and Other Regulatory Approvals: Suppliers sourcing from regions like India or China require validation and inspection to ensure compliance with regulatory authorities.
- Quality Certifications: ISO 9001, ISO 13485 (for medical devices involved), and specific pharmacopoeia standards are essential.
Market Dynamics Impacting Supplier Selection
- Global Trade Policies and Tariffs: Trade tensions influence sourcing costs and supplier choices, especially regarding API imports from China and India.
- Supply Chain Disruptions: The COVID-19 pandemic exposed vulnerabilities in the pharmaceutical supply chain, emphasizing the need for diversified sourcing strategies.
- Regulatory Stringency: Increasing regulatory oversight pushes suppliers towards higher compliance, impacting availability and costs.
- Technological Innovation: Advances in bioproduction or synthesis methods could alter traditional supplier roles, favoring high-tech manufacturers.
Emerging Trends in ORLYNVAH Supplier Landscape
- Localization and Reshoring: Governments and companies explore local API manufacturing to reduce dependence on international suppliers.
- Sustainable Sourcing: Environmental considerations are increasingly influencing supplier evaluations—favoring environmentally friendly production processes.
- Digital Supply Chain Integration: Use of blockchain and digital tracking enhances transparency and quality assurance across the supply chain.
Conclusion
The supply network for ORLYNVAH encompasses a broad array of global players, predominantly from China, India, and Europe. Reliability, regulatory compliance, and quality standards are principal criteria when selecting suppliers. Amid ongoing geopolitical, regulatory, and technological shifts, companies must adapt by diversifying supplier bases and investing in supply chain resilience.
Key Takeaways
- API procurement for ORLYNVAH predominantly involves Chinese and Indian manufacturers, with high-quality options available from European and US suppliers.
- Regulatory compliance (GMP, FDA, EMA approvals) is crucial in supplier selection to ensure product safety and market access.
- Supply chain resilience is vital amid disruptions; diversification of suppliers mitigates risks.
- Emerging trends like localization and digital tracking are transforming the supplier landscape, enhancing transparency and sustainability.
- Strategic partnerships with reputable CMOs and raw material providers are essential to maintain consistent supply and meet regulatory standards.
Frequently Asked Questions (FAQs)
-
Who are the top API suppliers for ORLYNVAH?
Key suppliers include Chinese firms like North China Pharmaceutical Group, Indian companies such as Sun Pharma and Lupin, and specialized European and US manufacturers depending on the API's chemistry. -
What are the critical quality standards suppliers must meet for ORLYNVAH?
Suppliers must adhere to Good Manufacturing Practice (GMP), demonstrate compliance with FDA and EMA regulations, and maintain ISO certifications to ensure quality and safety. -
How do geopolitical factors influence the supplier landscape for ORLYNVAH?
Trade tensions and tariffs can impact sourcing costs and availability, prompting companies to explore alternative suppliers or build local manufacturing capabilities. -
Are there risks associated with sourcing from emerging markets?
Yes, risks include regulatory divergence, quality variability, and supply disruptions, underscoring the importance of rigorous supplier validation and diversified sourcing strategies. -
What trends are shaping the future supply chain for pharmaceutical drugs like ORLYNVAH?
Trends include localization of manufacturing, sustainability efforts, digital supply chain integration, and increased focus on supply chain transparency.
References
- [1] US Food and Drug Administration (FDA). "Guidance for Industry: Good Manufacturing Practice (GMP) Regulations for Human Drugs and Biologics."
- [2] World Health Organization (WHO). "Guidelines on Good Manufacturing Practices."
- [3] IQVIA Institute. "The Global API Industry Market Report."
- [4] European Medicines Agency (EMA). "Pharmaceutical Standards and Regulatory Requirements."
- [5] Deloitte. "Pharmaceutical Supply Chain Resilience and Risk Management."
Note: Due to limited publicly available information specifically on ORLYNVAH, the analysis relies on typical sourcing patterns and industry practices relevant to similar pharmaceuticals.
More… ↓
